bemcentinib,pembrolizumab
bergenbio,merck
['pembro', 'bemcentinib']
lovely to see mist3 bemcentinib/pembro combo ph2 in relapsed meso- no prior io. n=26. orr 15.4%, as seen with prior io trials. higher axl tended to associate with disease control. await more trans data to figure out what bemcentinib is brining to combo #asco23 
Thoracic Oncologist @royalmarsdenNHS, Professor @ICR_London; Chair @BTOGorg; views are my own.